Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
BioPharma Dive
Thu, 03/7/24 - 11:05 am
Regenxbio
Duchenne Muscular Dystrophy
DMD
RGX-202
Sarepta Therapeutics
Elevidys
Sarepta’s Duchenne Gene Therapy Elevidys Nabs $200M on Strong Demand
BioSpace
Thu, 02/29/24 - 11:00 am
Sarepta Therapeutics
gene therapy
Elevidys
earnings
Duchenne Muscular Dystrophy
FDA to review Sarepta's Duchenne gene therapy for traditional approval
Reuters
Fri, 02/16/24 - 11:38 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Elevidys
Sarepta's next DMD drug seems to get the job done, but Elevidys casts long shadow
Fierce Biotech
Mon, 01/29/24 - 10:25 pm
Sarepta Therapeutics
DMD
SRP-5051
Elevidys
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Motley Fool
Thu, 01/25/24 - 11:01 am
Sarepta Therapeutics
Vertex Pharmaceuticals
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
Motley Fool
Mon, 01/22/24 - 10:13 pm
Sarepta Therapeutics
Elevidys
Sarepta begins screening in muscular dystrophy gene therapy trial
Clinical Trials Arena
Wed, 01/17/24 - 09:25 am
Sarepta Therapeutics
clinical trials
SRP-9003
limb-girdle muscular dystrophy
5 of the best paid biopharma CEOs
PharmaVoice
Mon, 11/13/23 - 10:10 am
Pharma CEOs
executive compensation
Sarepta Therapeutics
Royalty Pharma
Seagen
Zentalis
Pfizer
Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion
Fierce Pharma
Thu, 11/2/23 - 05:15 pm
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
Elevidys
gene therapy
Sarepta’s disappointing data put the FDA in a difficult spot
Stat
Tue, 10/31/23 - 10:16 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
DMD
FDA
gene therapy
Sarepta gene therapy for Duchenne misses main goal of key study
BioPharma Dive
Mon, 10/30/23 - 08:17 pm
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
clinical trials
FDA
Elevidys
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Sarepta offers early look at closely watched gene therapy launch
BioPharma Dive
Thu, 08/3/23 - 11:19 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Elevidys
drug launches
Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip
Fierce Pharma
Thu, 07/6/23 - 11:15 am
Sarepta Therapeutics
priority review vouchers
FDA
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Sarepta prices Duchenne gene therapy at $3.2M
BioPharma Dive
Fri, 06/23/23 - 09:44 am
Sarepta Therapeutics
drug pricing
DMD
Duchenne Muscular Dystrophy
Elevidys
FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
BioSpace
Thu, 06/22/23 - 10:51 pm
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
FDA
Elevidys
gene therapy
Biopharma Companies with the Biggest CEO-Employee Pay Gaps
BioSpace
Thu, 06/15/23 - 09:58 am
Pharma CEOs
executive compensation
Sarepta Therapeutics
Pfizer
Bausch + Lomb
Amneal Pharmaceuticals
Thermo Fisher
IQVIA
McKesson
Royalty Pharma
Charles Rivers Laboratories
Seagen
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »